ImmunoVaccine Technologies Inc. (IVT), announced today that it had signed licensing agreements for Pfizer Animal Health to apply IVT's novel VacciMax® vaccine platform to the potential development of future, particular livestock vaccines.

Although terms of the agreements were not disclosed, IVT will receive upfront signing fees, milestone and royalty payments.

"We are excited that Pfizer plans to commercialize our technology," said Dr. Randal Chase, president and CEO of ImmunoVaccine Technologies. “We look forward to further discussions with Pfizer to integrate the VacciMax® platform into more applications in the fields of animal health care."

About the VacciMax® Platform
The VacciMax® vaccine-enhancement platform is comprised of a mixture of liposomes and adjuvants. The VacciMax® platform significantly enhances antibody production. IVT has demonstrated that the VacciMax® platform not only improves humoral response, but also cell-mediated response (cytotoxic CTL). This is a novel technology that could aid the development of new vaccines in human and animal health applications, with potential for both therapeutic cancer applications and preventative infectious disease vaccines. In pre-clinical animal models, IVT’s research shows that the VacciMax® platform has the ability to greatly enhance the effectiveness of antigens and could provide a new way to treat a wide range of diseases.

About Pfizer Animal Health (WWW.PFIZERAH.COM)
Pfizer, Inc., the world’s largest research-based biomedical and pharmaceutical company, also is a world leader in discovering and developing innovative animal vaccines and prescription medicines.

ImmunoVaccine Technologies Inc. (IVT) is a clinical stage vaccine development company focused on commercialization of its novel vaccine candidates.

DISCLOSURE NOTICE: The information contained in this release is as of January 14, 2008. IVT assumes no obligation to update any forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about IVT’s vaccine-enhancement platform, including its potential to aid the development of new vaccines in human and animal health applications, that involves substantial risks and uncertainties. Such risks and uncertainties include, among others, the uncertainties inherent in research and development; decisions by regulatory authorities regarding whether and when to approve any such vaccines; and competitive developments.

For more information, please contact:
Brian Lowe, Vice President
ImmunoVaccine Technologies Inc.

Jennifer Ayotte
Impact Communications Group

Rick Goulart, Director of Public Relations
Pfizer Animal Health Inc.

Halifax, Nova Scotia, January 14, 2008